United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - chromic chloride hexahydrate, quantity: 5.33 microgram/ml; ferric chloride hexahydrate, quantity: 540 microgram/ml; sodium selenite, quantity: 17.29 microgram/ml; sodium fluoride, quantity: 210 microgram/ml; cupric chloride dihydrate, quantity: 102.3 microgram/ml; potassium iodide, quantity: 16.6 microgram/ml; sodium molybdate dihydrate, quantity: 4.85 microgram/ml; manganese chloride tetrahydrate, quantity: 19.79 microgram/ml; zinc chloride, quantity: 1.05 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; xylitol - to meet basal to moderately increased requirements of trace elements in parenteral nutrition in adults, when either oral or enteral nutrition is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: sodium sulfate; sulfuric acid; sodium acetate trihydrate; water for injections - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium acetate trihydrate; sodium sulfate; sulfuric acid - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

reyoung pharmaceutical co. ltd. - cefuroxime (cefuroxime sodium) - powder for solution for injection/infusion - 750mg

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefuroxime sodium - powder for solution for injection/infusion - 1.5 gram(s) - second-generation cephalosporins; cefuroxime

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefuroxime sodium - powder for solution for injection/infusion - 750 milligram(s) - second-generation cephalosporins; cefuroxime

Ireland - English - HPRA (Health Products Regulatory Authority)

stravencon ltd - cefuroxime sodium - powder for solution for injection/infusion - 1500 milligram(s) - second-generation cephalosporins; cefuroxime

Malta - English - Medicines Authority

elpen pharmaceutical co. inc. 95 marathonos ave., 190 09 pikermi, attica, greece - cefuroxime - powder for solution for injection - cefuroxime 750 mg - antibacterials for systemic use

Malta - English - Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - powder for solution for infusion or injection - cefuroxime sodium 750 mg - antibacterials for systemic use